STOCK TITAN

Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the addition of its shares to the MSCI World Micro Cap Index effective December 1, 2021. This decision, made public on November 11, 2021, reflects Regencell's growing recognition within the investment community. The MSCI World Micro Cap Index includes 6,192 constituents and covers around 1% of the free float-adjusted market capitalization across 23 developed countries. CEO Yat-Gai Au expressed optimism that this milestone will boost the company's visibility among institutional investors.

Positive
  • Inclusion in the MSCI World Micro Cap Index may enhance investor visibility.
  • The MSCI index covers micro-cap representation across 23 developed countries.
Negative
  • None.

HONG KONG--(BUSINESS WIRE)-- Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced that the ordinary shares of the Company will be added to the MSCI World Micro Cap Index on November 30, 2021 after the close of market (effective December 1, 2021).

MSCI Inc., a leading provider of research-based indexes and analytics, announced Regencell’s addition on November 11, 2021, following results of their semi-annual index review. Launched on December 1, 2010, the MSCI World Micro Cap Index captures micro-cap representation across 23 Developed Markets countries. With 6,192 constituents, the index covers approximately 1% of the free float-adjusted market capitalization in each country, as of October 29, 2021.

Mr. Yat-Gai Au, Regencell’s Chairman & CEO noted, “We are pleased to be included in the 2021 MSCI World Micro Cap Index as we believe this international index is a benchmark for institutions investing in global micro caps. 2021 has been an exciting year for Regencell, and we expect this new milestone to increase our visibility with investors that refer to MSCI indexes as a key part of their investment strategy.”

About Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited is an early-stage bioscience company that commenced operations in Hong Kong is 2014. Regencell focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID-19 (“COVID”). Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently to other markets as it deems appropriate. The Company formed a joint venture to offer COVID related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. Such forward-looking statements include the business plan of the joint venture, objectives, expectations and intentions of the joint venture parties, and Regencell’s estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, our actual results may differ materially from our expectations or projections. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: there is uncertainty about the spread of the COVID-19 virus and the impact it will have on expected operations of the joint venture, the demand for the planned COVID TCM treatments. These and other risks and uncertainties are detailed in the other public filings with the Securities and Exchange Commission (the “SEC”) by Regencell.

Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

For more information:

Corporate:

James Chung

COO & CSO

Regencell Bioscience Holdings Limited

ir@rgcbio.com

Investors outside of Asia Region:

Lena Cati

The Equity Group Inc.

Vice President

(212) 836-9611

lcati@equityny.com

Investors in Asia Region:

Strategic Financial Relations Limited

Vicky Lee (852) 2864 4834

Brigid Lee (852) 2114 4313

Yvonne Lee (852) 2864 4847

SPRG_Regencell@sprg.com.hk

Source: Regencell Bioscience Holdings Limited

FAQ

When will Regencell Bioscience Holdings Limited be added to the MSCI World Micro Cap Index?

Regencell will be added to the MSCI World Micro Cap Index effective December 1, 2021.

What does the inclusion in the MSCI World Micro Cap Index mean for RGC?

Inclusion in the index is expected to increase Regencell's visibility among institutional investors.

How many constituents are in the MSCI World Micro Cap Index?

The MSCI World Micro Cap Index includes 6,192 constituents.

What is the significance of the MSCI World Micro Cap Index?

The MSCI World Micro Cap Index serves as a benchmark for institutions investing in global micro-cap stocks.

Regencell Bioscience Holdings Limited Ordinary Shares

NASDAQ:RGC

RGC Rankings

RGC Latest News

RGC Stock Data

48.28M
13.01M
88.76%
0.13%
0.03%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Causeway Bay